A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the anti-tumor activity, safety, and
tolerability of telatinib when used in combination with chemotherapy (capecitabine and
cisplatin) as first-line therapy in subjects with advanced gastric cancer. The primary
objective is to assess progression free survival (PFS) in subjects receiving telatinib in
combination with chemotherapy (capecitabine and cisplatin). The secondary objectives are to
assess overall survival, overall response rate, safety and tolerability, pharmacokinetics and
biomarkers.